Reed Joshua, the Chief Financial Officer of Alkermes plc, has reported significant stock transactions in a recent SEC filing. This filing, dated October 9, 2026, details his acquisition and disposition of shares, reflecting ongoing compensation strategies within the pharmaceutical industry.
Background
Alkermes plc, based in Dublin, Ireland, operates in the pharmaceutical preparations sector (SIC 2834). The company is publicly traded under the ticker symbol ALKS. Reed Joshua has been actively involved in the company, as indicated by his recent filings, which include multiple transactions over the past year.
What the Filing Says
The SEC filing reveals that on October 8, 2026, Reed Joshua acquired 9,164 ordinary shares through a transaction coded as 'M' for acquisition. Additionally, he disposed of 4,069 shares at a price of $40.11 each, resulting in a total of 5,095 shares remaining post-transaction. The filing notes that these shares are part of a restricted stock unit award, which vests in four equal annual installments starting from the date of the transaction.
Impact
This update may influence investor perceptions regarding Alkermes' executive compensation practices and overall governance. The pharmaceutical sector often faces scrutiny regarding executive stock transactions, as they can signal confidence in the company’s future performance. Stakeholders may closely monitor Joshua's transactions as a reflection of his commitment to the company.
What's Next
The filing does not say what happens next.